IGBA PROFILE

IGBA Statement at the 66th Series of Meetings of the WIPO Assemblies (July 2025) Publications S T U D I E S A N D A C T I V I T I E S Gaming the System: An overview of originator companies' evergreening strategies used to hinder access to generic and biosimilar products (January 2025) Constituency Statement: WHO's Executive Board Meeting 158 (February 2026) IGBA position on Streamlined Development (2024) In Support of Global Comparator for Biosimilars—Waiving bridging studies concerning local versus global reference products (2024) O U R L A T E S T MORE INFORMATION For more details, regarding IGBA and its member associations, see the IGBA website at : WWW.IGBAMEDICINES.ORG Importance of Single Global Development of Generic and Biosimilar Medicines for Patient Access (December2025)” The IGBA CEO Advisory Committee: Patient Access, Industry Value, and Global Cooperation in a Reshaping World (December 2025)